Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
Authors:
- Danai DimaDDDanai Dima
- Fauzia UllahFUFauzia Ullah
- Sandra MazzoniSMSandra Mazzoni
- Louis WilliamsLWLouis Williams
- Beth FaimanBFBeth Faiman
- Austin KurkowskiAKAustin Kurkowski
- Chakra ChaulagainCCChakra Chaulagain
- Shahzad RazaSRShahzad Raza
- Christy SamarasCSChristy Samaras
- Jason ValentJVJason Valent
- Jack KhouriJKJack Khouri
- Faiz AnwerFAFaiz Anwer
Open Access
Abstract
Multiple myeloma (MM) is the second most common hematologic malignancy in adults worldwide. Over the past few years, major therapeutic advances have improved progression-free and overall survival, as well as quality of life. Despite this recent progress, MM remains incurable in the vast majority of cases. Patients eventually relapse and become refractory to multiple drug classes, making long-term management challenging. In this review, we will focus on the treatment paradigm of relapsed/refractory MM (RRMM) in the era of advanced therapies emphasizing the available novel modalities that have recently been incorporated into routine practice, such as chimeric antigen receptor T-cell therapy, bispecific antibodies, and other promising approaches. We will also discuss major factors that influence the selection of appropriate drug combinations or cellular therapies, such as relapse characteristics, and other disease and patient related parameters. Our goal is to provide insight into the currently available and experimental therapies for RRMM in an effort to guide the therapeutic decision-making process.Keywords
This publication has 249 references indexed in Scilit:
- Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II studyBlood Cancer Journal, 2013
- Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaHaematologica, 2013
- Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsHaematologica, 2012
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation studyBlood, 2012
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialThe Lancet Oncology, 2011
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple MyelomaJournal of Clinical Oncology, 2009
- Lenalidomide in renal insufficiency – balancing the risks and benefitsBritish Journal of Haematology, 2009
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005